• Mendus’ third-quarter 2026 net loss widened 19% year-over-year to SEK 22.69 million.
• Quarter-end cash rose 48% year-over-year to SEK 55.71 million, with cash runway extending into the second quarter of 2027.
• The Phase 1b DIVA trial began evaluating vididencel with venetoclax and azacitidine in newly diagnosed AML patients ineligible for intensive chemotherapy.
• An independent safety review found no safety or tolerability concerns in VITAL-CML’s first stage, supporting continued development and VITAL-TFR2 initiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mendus AB (publ) published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.